JREE:F:F-JPMorgan ETFs (Ireland) ICAV - Europe Research Enhanced Index Equity UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 46.125

Change

-0.43 (-0.92)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-29 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.09 (-0.17%)

USD 128.40B
SXR8:F iShares Core S&P 500 UCITS ETF..

-3.16 (-0.57%)

USD 114.04B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 108.41B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 52.77B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 52.44B
VUSA:F Vanguard Funds Public Limited ..

-0.53 (-0.53%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 46.87B
0ZC:F Zscaler Inc

+15.30 (+6.77%)

USD 37.92B
BSND:F Danone SA

+0.10 (+0.68%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

-0.72 (-0.57%)

USD 24.77B

ETFs Containing JREE:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.36% 80% B- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.36% 80% B- 71% C-
Trailing 12 Months  
Capital Gain 6.99% 61% D- 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.99% 59% D- 54% F
Trailing 5 Years  
Capital Gain 79.68% 76% C+ 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 79.68% 76% C+ 54% F
Average Annual (5 Year Horizon)  
Capital Gain 11.21% 76% C+ 69% C-
Dividend Return 11.21% 74% C 60% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.57% 63% D 90% A-
Risk Adjusted Return 106.04% 94% A 95% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike